A Phase II Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

The purpose of this study is to determine the efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma and also to determine the safety of the combination.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.



  • drug : Capecitabine
  • drug : Thalidomide

Phase: Phase 2


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Able to comprehend and sign an IRB approved Informed consent - Willingness and ability to comply with the FDA-mandated S.T.E.P.S. program. - Male or female 18 years or older - Willing to use contraception - Pathologic diagnosis of renal cell carcinoma - Bi-dimensionally measurable disease - Evidence of disease progression prior to start of treatment - Failed prior immunotherapy or unwilling/unable to receive prior immunotherapy - Adequate hematologic data: ANC.1.5; platelets>100x10^9 - Adequate renal function: Creatinine clearance .50cc - Adequate liver function: Alkaline phos <3XULN AST/ALT <3XULN T.Bili <1.5XULN - ECOG performance status 0-1

External Links

Explore related trials

Contact information

Primary Contact:

Denise Haas 6507361252

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: